{
    "clinical_study": {
        "@rank": "33682", 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the effectiveness of giving indinavir plus efavirenz\n      plus adefovir dipivoxil to patients who have failed treatment with nelfinavir and patients\n      who have never taken a protease inhibitor (PI). Effectiveness is measured by the number of\n      patients who have a viral load (level of HIV in the blood) below 400 copies/ml after 48\n      weeks of treatment."
        }, 
        "brief_title": "Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this open-label, nonrandomized study, 120 HIV-infected patients are stratified into two\n      groups: failed nelfinavir vs protease inhibitor-naive.  All patients receive indinavir plus\n      efavirenz plus adefovir dipivoxil plus and L-carnitine, orally.  Plasma vRNA is measured\n      every 4 weeks until Week 16, then every 8 weeks for the remainder of the 48-week study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Serologically documented HIV infection.\n\n          -  Baseline CD4 count greater than or equal to 50 cells and vRNA greater than or equal\n             to 10,000 copies/ml.\n\n          -  Parental consent for patients under 18.\n\n        Nelfinavir-Failure Group:\n\n          -  Must have protease inhibitor experience solely with nelfinavir and be considered\n             drug-adherent.\n\n          -  Must be candidate for changing therapy because of virologic failure and be receiving\n             nelfinavir at entry (at least 16 weeks of nelfinavir plus NRTI therapy with at least\n             a 10-fold decline in vRNA due to nelfinavir therapy and a subsequent increase toward\n             the patient's baseline vRNA of at least 10-fold).\n\n        Control Group:\n\n          -  Must have received any combination of currently licensed nucleoside reverse\n             transcriptase inhibitors for at least 16 weeks.\n\n          -  Must be naive to efavirenz, adefovir dipivoxil, and other NRTI's.\n\n        Exclusion Criteria\n\n        Prior Medication:\n\n        Excluded:\n\n        Control group:\n\n          -  Prior efavirenz, adefovir dipivoxil, or other non-nucleoside reverse transcriptase\n             inhibitors.\n\n        Required:\n\n        Nelfinavir-failure patients:\n\n          -  At least 16 weeks of nelfinavir.\n\n        Control group:\n\n          -  At least 16 weeks of any combination of currently licensed nucleoside reverse\n             transcriptase inhibitors."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": "120", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00002242", 
            "nct_id": "NCT00002220", 
            "org_study_id": "246N", 
            "secondary_id": "075-00"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Efavirenz", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Levocarnitine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Adefovir dipivoxil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carnitine", 
                "Adefovir", 
                "Adefovir dipivoxil", 
                "Indinavir", 
                "Nelfinavir", 
                "Efavirenz", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "keyword": [
            "Drug Resistance", 
            "Drug Therapy, Combination", 
            "Antiviral Agents", 
            "HIV Protease Inhibitors", 
            "Indinavir", 
            "RNA, Viral", 
            "Adenine", 
            "efavirenz"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "LAC / USC Med Ctr / Infectious Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06510"
                    }, 
                    "name": "Yale Univ / AIDS Clinical Trials Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "Delaware", 
                        "zip": "19899"
                    }, 
                    "name": "Med Ctr of Delaware"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii", 
                        "zip": "96816"
                    }, 
                    "name": "Hawaii AIDS Clinical Trial Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "606123832"
                    }, 
                    "name": "Rush Presbyterian Saint Lukes Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "212876220"
                    }, 
                    "name": "Johns Hopkins Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia Presbyterian Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stonybrook", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "117948153"
                    }, 
                    "name": "AIDS TMT Unit / Univ Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37212"
                    }, 
                    "name": "Vanderbilt Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75219"
                    }, 
                    "name": "Oaklawn Physicians Group"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Multi-Center, Open-Label Study of the Effect of Indinavir, Efavirenz, and Adefovir Dipivoxil Combination Therapy in Patients Who Have Failed Nelfinavir", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002220"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1999"
    }, 
    "geocoordinates": {
        "AIDS TMT Unit / Univ Hosp": "40.996 -74.344", 
        "Columbia Presbyterian Hosp": "40.714 -74.006", 
        "Hawaii AIDS Clinical Trial Unit": "21.307 -157.858", 
        "Johns Hopkins Hosp": "39.29 -76.612", 
        "LAC / USC Med Ctr / Infectious Diseases": "34.052 -118.244", 
        "Massachusetts Gen Hosp": "42.358 -71.06", 
        "Med Ctr of Delaware": "39.746 -75.547", 
        "Oaklawn Physicians Group": "32.803 -96.77", 
        "Rush Presbyterian Saint Lukes Med Ctr": "41.878 -87.63", 
        "Vanderbilt Clinic": "36.166 -86.784", 
        "Yale Univ / AIDS Clinical Trials Unit": "41.308 -72.928"
    }
}